Navigation Links
AstraZeneca Offers Online Enrollment and Additional Improvements to Patient Assistance Program
Date:1/13/2010

WILMINGTON, Del., Jan. 13 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) announced today that enrollment and re-enrollment for two of its prescription savings programs is available online for the first time at www.azandme.com.

In addition, online self-service options are available for both programs, which enable health care providers, advocates and patients to order and monitor the shipping of refills and check the status of their enrollment online at www.azandme.com. AstraZeneca is the first pharmaceutical company to provide these self-service options directly to patients.

"We are using more tools to help patients get the medicines and information they need in an efficient and timely way," said Jennifer McGovern, AstraZeneca Director of Patient Assistance Programs. "We hope to be able to better serve patients and the people who support them by continually making program enhancements."

For over 30 years, AstraZeneca has offered patient assistance, because the company knows that medicines can only make a difference if patients can access them. Web-based improvements are another way that AstraZeneca is strengthening its commitment to patient health.

Program Details

To learn more about the program, get a list of available medicines, or to see if you
'/>"/>

SOURCE AstraZeneca
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Novexel to be Acquired by AstraZeneca
2. AstraZeneca Medicare Part D Patient Assistance Program No Longer Requires Co-Pays
3. U.S. Court of Appeals Upholds AstraZeneca AWP Settlement
4. Emerging Agents from Theravance/Astellas, Johnson & Johnson/Basilea and Forest/Astrazeneca/Takeda Will Drive Modest Growth in the MRSA Drug Market Through 2018
5. Dr. Steven M. Paul to Retire from Lilly as Executive Vice President, Science and Technology, President, Lilly Research Laboratories; Dr. Jan M. Lundberg, Executive Vice President, Head of Global Discovery Research, AstraZeneca, Named his Successor
6. Jubilant Enters Research Collaboration With AstraZeneca
7. AstraZeneca Submits NDA for Low Dose Aspirin/Esomeprazole Combination Product
8. AstraZenecas Partner, MAP Pharmaceuticals, Announces Phase 3 Study of Unit Dose Budesonide in Children with Asthma Did Not Meet Primary Endpoints
9. AstraZeneca Responds to FDA Joint Advisory Committees Recommendation on SYMBICORT(R)
10. AstraZeneca and Targacept Announce Top-Line Results from Phase IIb Study of AZD3480 in Cognitive Dysfunction in Schizophrenia
11. AstraZeneca Receives Six Months Pediatric Exclusivity for CASODEX(R) (bicalutamide) from the FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... VILLAGE, Nev. , June 29, 2015  PDL ... it has entered into a credit agreement with CareView ... with up to $40 million of secured debt financing. ... industry focused on patient care monitoring. Under ... to $40 million of debt financing in two tranches ...
(Date:6/29/2015)... NESS ZIONA, Israel , ... Ltd. (Nasdaq: BVXV, TASE: BVXV) today announced positive preliminary ... M-001, BiondVax,s candidate for a universal influenza vaccine. In ... the ages of 50 to 65, followed by an ... 3 weeks later. M-001 was found to be safe ...
(Date:6/29/2015)... , June 29, 2015 DURECT ... James E. Brown , President and CEO, ... Conference on Wednesday, July 8 at 11:45 a.m. ... Le Parker Meridien Hotel in New York City.  ... may request a one-on-one meeting through the conference ...
Breaking Medicine Technology:PDL BioPharma Announces $40 Million Financing Transaction with CareView Communications 2PDL BioPharma Announces $40 Million Financing Transaction with CareView Communications 3PDL BioPharma Announces $40 Million Financing Transaction with CareView Communications 4BiondVax Presents BVX-006 Preliminary Phase II Results: the Universal Flu Vaccine at Higher Doses is Safe and Improves Immunogenicity in Older Adults 2BiondVax Presents BVX-006 Preliminary Phase II Results: the Universal Flu Vaccine at Higher Doses is Safe and Improves Immunogenicity in Older Adults 3DURECT to Present at the Cantor Fitzgerald Healthcare Conference 2
... risk of,stroke by 34% in patient with atrial fibrillation or ... adequately treated by antithrombotic ... a,post-hoc analysis of the data from the ATHENA study were ... Society of Cardiology,congress 2008, in Munich, Germany. Previous results from ...
... in Subjects with ALS, RICHMOND, Calif., Sept. 3 ... that it has opened a Phase,2 clinical trial (SB-509-801) ... progressive, degenerative motor-neuron disease for which there,are limited treatment ... an injectable formulation of a plasmid,encoding a zinc finger ...
Cached Medicine Technology:Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 2Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 3Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 4Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 5Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 2Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 3Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 4Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 5
(Date:6/30/2015)... ... June 30, 2015 , ... Experts estimate that up to 80% ... pain can range from a dull, constant ache (chronic) to a sudden sharp pain ... steroid injections, selective nerve root blocks and rhizotomy treatment, OPTIMAL Pain & Regenerative ...
(Date:6/30/2015)... Las Vegas, NV (PRWEB) , ... June 30, ... ... has recently returned to the U.S. after a 5-day tour in India. ... that are currently collaborating with Trivedi Master Wellness™ and Transformational Leader/Internationally ...
(Date:6/30/2015)... CT (PRWEB) , ... June 30, 2015 , ... ... on Wednesday, June 24, 2015 amidst bright skies and inspirational words. , ... the cherished processional walk from the Glenholme building to the school’s Center for ...
(Date:6/30/2015)... ... June 30, 2015 , ... Healthy and productive interpersonal ... outcomes. According to Dr. Theo Wubbels (Professor of Education, Admissions Dean, Utrecht ... to show “all kinds of behavior when the situation asks for it.” ...
(Date:6/30/2015)... ... June 30, 2015 , ... Scott Purdy, the spokesperson ... to Provider XO. Scott Purdy stated that the XO stands for eXtra Operability (XO) ... automate the workflow processes of the Revenue Cycle. , Provider XO, based in ...
Breaking Medicine News(10 mins):Health News:OPTIMAL Pain & Regenerative Medicine Brings Innovative Back Pain Management Options Including PRP Injections and Stem Cell-like Therapies to Dallas/Ft. Worth Metroplex 2Health News:OPTIMAL Pain & Regenerative Medicine Brings Innovative Back Pain Management Options Including PRP Injections and Stem Cell-like Therapies to Dallas/Ft. Worth Metroplex 3Health News:Trivedi Global Inc. CEO Visits India to Finalize Science Projects to Create Anti-Aging, Overall Health and Probiotic Products with Help of a Multi-Billion Dollar Company 2Health News:Trivedi Global Inc. CEO Visits India to Finalize Science Projects to Create Anti-Aging, Overall Health and Probiotic Products with Help of a Multi-Billion Dollar Company 3Health News:The Glenholme School Graduates Its Class of 2015 2Health News:The Glenholme School Graduates Its Class of 2015 3Health News:The Glenholme School Graduates Its Class of 2015 4Health News:Lessons On Leadership - Top 12 Global Teacher Bloggers Reveal the Best Strategies for Building Positive Leadership in Global Classrooms 2Health News:Dephinitive Systems Is Getting a New Name 2
... HealthDay Reporter , MONDAY, Jan. 23 (HealthDay News) -- Since ... questioned the safety of medical procedures used to terminate pregnancy. ... abortion is safer than carrying a baby to term. ... delivery is 8.8 deaths per 100,000, while the risk of ...
... world media, researchers, academics including several from Simon Fraser ... the Vancouver Convention Centre Feb. 16-20. , Simon Fraser University,s ... of a bell announcing the 2012 AAAS (American Association ... Aquarium yesterday. , "The AAAS conference is a must for ...
... MRI helps surgeons make more informed decisions about nerve-sparing ... new study published online in the journal Radiology ... most common cancer diagnosed in American men, according to ... prostatectomy, or removal of the prostate, is a common ...
... Jan. 24, 2012) For men diagnosed ... drug dutasteride ("Avodart") delays disease progression and initiating active ... a three-year international clinical trial led by Dr. Neil ... Network (UHN). The findings are published online ...
... Wakeling is adding to the arsenal of increasingly sophisticated ... viewing muscle activation details that have never been seen ... movement in people and animals, Wakeling has developed a ... proprietary data-processing software to scan and capture 3D maps ...
... By Randy Dotinga HealthDay Reporter , MONDAY, Jan. ... be bad for you, a new study finds that parts of ... with others. It,s not clear how this effect of stress ... system -- which cause inflammation in the body -- have been ...
Cached Medicine News:Health News:Abortion Safer for Women Than Childbirth, Study Claims 2Health News:Abortion Safer for Women Than Childbirth, Study Claims 3Health News:SFU hits hot buttons at 2012 AAAS conference 2Health News:SFU hits hot buttons at 2012 AAAS conference 3Health News:Preoperative MRI may reduce risk of nerve damage in prostate cancer surgeries 2Health News:Prostate cancer study proves drug delays disease progression 2Health News:Study Shows How Stress Triggers Immune System 2Health News:Study Shows How Stress Triggers Immune System 3
... acetabular cup system has been designed to ... tri-spiked and cluster hole configurations. The objective ... micromotion on three primary modes: Tilt, migration ... features result in initial and long-term fixation. ...
Optimal solution for normal acetabulum....
Optimal solution for normal acetabulum....
Biopro rimmed acetabular is manufactured from titanium and is porous coated on the outside of its shell. The rimmed acetabular accommodates a polyethylene inert....
Medicine Products: